Clinical efficacy of Angong Jiangya pill for grade 2 hypertension with liver-fire hyperactivity syndrome: a randomized, double-blind, placebo-controlled, multicenter trial.
AGJY demonstrated efficacy in lowering BP, increasing the rate of BP compliance, and improving TCM symptoms and quality of life in patients with grade 2 hypertension liver-fire hyperactivity syndrome. However, further in-depth studies are required to determine the mechanism of TCM in treating hypertension.
Authors
- Zhenmin Zhang (ORCID: https://orcid.org/0000-0002-0078-7873)
- Wenlong Xing (ORCID: https://orcid.org/0000-0001-8839-665X)
- Hongxu Liu (ORCID: https://orcid.org/0000-0002-4198-7417)
- Lan Xiang (ORCID: https://orcid.org/0000-0001-6595-2836)
- Haoyu Jing (ORCID: https://orcid.org/0000-0002-3450-2928)
- Juju Shang (ORCID: https://orcid.org/0000-0002-5459-4671)
- Lai Xiaolei
Institutions
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.19852/j.cnki.jtcm.2025.02.010
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00